Clinical trial
Multicenter, Rising, Multiple-Dose, Placebo-Controlled, Dose-Response Study to Evaluate the Safety, Tolerability, and Anti-Viral Activity of 4 Weeks of Treatment With 200-800 Mg Fozivudine Tidoxil in Patients With HIV-1 Infection (MF4314).
NCT00002385 is registered in ClinicalTrials.gov with Anderson Clinical Research as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multicenter, Rising, Multiple-Dose, Placebo-Controlled, Dose-Response Study to Evaluate the Safety, Tolerability, and Anti-Viral Activity of 4 Weeks of Treatment With 200-800 Mg Fozivudine Tidoxil in Patients With HIV-1 Infection (MF4314).
- Lead sponsor
- Anderson Clinical Research
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- Not reported
- Completion date
- Not reported
- Enrollment
- 60
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.